
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is a promising biopharmaceutical firm with a strong presence in the cancer treatment market thanks to its successful drug, Cabometyx. The company continues to see growth in script sales and has a durable, cash-generative franchise. However, there are inherent risks in drug development and the looming 2031 LOE for Cabometyx raises the stakes for their next leg, potentially leading to a need for additional financing.
Bears say
Exelixis is a biotechnology company that has seen a significant decrease in net income due to a $51.7 million impairment of long-lived assets. While the company has a promising pipeline, particularly with the development of zanzalintinib and an early-stage ADC platform, their flagship product Cabometyx will face LOEs in 2031 and the company has only a Hold rating at this time.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares